Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Urinary estrogen metabolites and breast cancer : a combined analysis of individual level data. / Dallal, Cher M; Stone, Roslyn A; Cauley, Jane A; Ness, Roberta B; Vogel, Victor G; Fentiman, Ian S; Fowke, Jay H; Krogh, Vittorio; Loft, Steffen; Meilahn, Elaine N; Muti, Paola; Olsen, Anja; Overvad, Kim; Sieri, Sabina; Tjønneland, Anne; Ursin, Giske; Wellejus, Anja; Taioli, Emanuela.
In: International Journal of Biological Markers, Vol. 28, No. 1, 2013, p. e3-e16.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Urinary estrogen metabolites and breast cancer
T2 - a combined analysis of individual level data
AU - Dallal, Cher M
AU - Stone, Roslyn A
AU - Cauley, Jane A
AU - Ness, Roberta B
AU - Vogel, Victor G
AU - Fentiman, Ian S
AU - Fowke, Jay H
AU - Krogh, Vittorio
AU - Loft, Steffen
AU - Meilahn, Elaine N
AU - Muti, Paola
AU - Olsen, Anja
AU - Overvad, Kim
AU - Sieri, Sabina
AU - Tjønneland, Anne
AU - Ursin, Giske
AU - Wellejus, Anja
AU - Taioli, Emanuela
PY - 2013
Y1 - 2013
N2 - Background: Circulating estrogens are associated with increased breast cancer risk, yet the role of estrogen metabolites in breast carcinogenesis remains unclear. This combined analysis of 5 published studies evaluates urinary 2-hydroxyestrone (2-OHE1), 16a-hydroxyestrone (16a-OHE1), and their ratio (2:16a-OHE1) in relation to breast cancer risk. ¿Methods: Primary data on 726 premenopausal women (183 invasive breast cancer cases and 543 controls) and 1,108 postmenopausal women (385 invasive breast cancer cases and 723 controls) were analyzed. Urinary estrogen metabolites were measured using enzyme linked immunosorbent assays. Study-specific and combined multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated based on tertiles of estrogen metabolites. Multinomial logistic regression models were fit according to hormone receptor status.¿Results: Higher premenopausal 2:16a-OHE1 was suggestive of reduced breast cancer risk overall (study-adjusted ORIIIvsI=0.80; 95% CI: 0.49-1.32) and for estrogen receptor negative (ER-) subtype (ORIIIvsI=0.33; 95% CI: 0.13-0.84). Among postmenopausal women, 2:16a-OHE1 was unrelated to breast cancer risk (study-adjusted ORIIIvsI=0.93; 95% CI: 0.65-1.33); however, the association between 2-OHE1 and risk varied by body mass index (p-interaction=0.003). ¿Conclusions: Premenopausal urinary 2:16a-OHE1 may play a role in breast carcinogenesis; however, larger studies are needed. Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16a-OHE1 overall, although obesity may modify associations with 2-OHE1.
AB - Background: Circulating estrogens are associated with increased breast cancer risk, yet the role of estrogen metabolites in breast carcinogenesis remains unclear. This combined analysis of 5 published studies evaluates urinary 2-hydroxyestrone (2-OHE1), 16a-hydroxyestrone (16a-OHE1), and their ratio (2:16a-OHE1) in relation to breast cancer risk. ¿Methods: Primary data on 726 premenopausal women (183 invasive breast cancer cases and 543 controls) and 1,108 postmenopausal women (385 invasive breast cancer cases and 723 controls) were analyzed. Urinary estrogen metabolites were measured using enzyme linked immunosorbent assays. Study-specific and combined multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated based on tertiles of estrogen metabolites. Multinomial logistic regression models were fit according to hormone receptor status.¿Results: Higher premenopausal 2:16a-OHE1 was suggestive of reduced breast cancer risk overall (study-adjusted ORIIIvsI=0.80; 95% CI: 0.49-1.32) and for estrogen receptor negative (ER-) subtype (ORIIIvsI=0.33; 95% CI: 0.13-0.84). Among postmenopausal women, 2:16a-OHE1 was unrelated to breast cancer risk (study-adjusted ORIIIvsI=0.93; 95% CI: 0.65-1.33); however, the association between 2-OHE1 and risk varied by body mass index (p-interaction=0.003). ¿Conclusions: Premenopausal urinary 2:16a-OHE1 may play a role in breast carcinogenesis; however, larger studies are needed. Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16a-OHE1 overall, although obesity may modify associations with 2-OHE1.
U2 - 10.5301/JBM.2012.9353
DO - 10.5301/JBM.2012.9353
M3 - Journal article
C2 - 22865302
VL - 28
SP - e3-e16
JO - International Journal of Biological Markers
JF - International Journal of Biological Markers
SN - 0393-6155
IS - 1
ER -
ID: 45487904